# MONALEESA-3 (NCT02422615)

> Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02422615
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Advanced Breast Cancer
- Interventions: Ribociclib; Fulvestrant; Placebo
- Enrollment: 726
- Primary outcome: Progression Free Survival (PFS) Per Investigator Assessment

## Commentary we found

- Podcasts: 10
- YouTube: 9
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=monaleesa-3-nct02422615

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02422615", "email": "<work email>"}; the inbox owner confirms by the emailed link.